Aurinia Pharmaceuticals Inc $AUPH Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 15.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,075 shares of the biotechnology company’s stock after selling 22,037 shares during the quarter. Invesco Ltd. owned approximately 0.09% of Aurinia Pharmaceuticals worth $981,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Aurinia Pharmaceuticals by 34.1% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 746,229 shares of the biotechnology company’s stock valued at $6,000,000 after purchasing an additional 189,775 shares during the period. Deutsche Bank AG grew its position in shares of Aurinia Pharmaceuticals by 76.7% in the first quarter. Deutsche Bank AG now owns 252,446 shares of the biotechnology company’s stock valued at $2,030,000 after purchasing an additional 109,577 shares during the period. Jupiter Asset Management Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at about $6,052,000. Kazazian Asset Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $84,000. Finally, XTX Topco Ltd grew its holdings in shares of Aurinia Pharmaceuticals by 148.9% during the first quarter. XTX Topco Ltd now owns 106,435 shares of the biotechnology company’s stock worth $856,000 after buying an additional 63,681 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Down 2.6%

AUPH stock opened at $11.68 on Wednesday. The firm has a market cap of $1.54 billion, a PE ratio of 27.16 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The firm’s 50 day moving average price is $10.05 and its 200-day moving average price is $8.73. Aurinia Pharmaceuticals Inc has a one year low of $6.42 and a one year high of $12.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on AUPH shares. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada boosted their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $12.00.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 5th. The shares were purchased at an average cost of $11.68 per share, with a total value of $2,336,000.00. Following the purchase, the director directly owned 11,329,500 shares in the company, valued at approximately $132,328,560. This represents a 1.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have purchased 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is owned by corporate insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.